anonymous
Guest
anonymous
Guest
VBU has jumped the shark. Judy and Kim thinking growing Shingrix immunization rates is driven by reach and frequency to HCP’s A&B.
VBU has jumped the shark. Judy and Kim thinking growing Shingrix immunization rates is driven by reach and frequency to HCP’s A&B.
Right?!!!
It’s amazing how handing an ipad back to a no see hcp 6 times in a quarter, to sign for samples, worked to grow NRXs lol!! This is a foolish dream that STEM and analytics team have shoved down upper managements throats whom seem to be out of touch with the reality of the healthcare environment we work in today. Some reps can make the change in a single visit others might take a year or two!
Would love to be in front of all my key doctors as much as respectfully possible, but it’s not reality!!!!!!!! Not to mention our very important NPs and PAs drive tons of rxs and I don’t see them on any target lists!!
Right?!!!
It’s amazing how handing an ipad back to a no see hcp 6 times in a quarter, to sign for samples, worked to grow NRXs lol!! This is a foolish dream that STEM and analytics team have shoved down upper managements throats whom seem to be out of touch with the reality of the healthcare environment we work in today. Some reps can make the change in a single visit others might take a year or two!
Would love to be in front of all my key doctors as much as respectfully possible, but it’s not reality!!!!!!!! Not to mention our very important NPs and PAs drive tons of rxs and I don’t see them on any target lists!!
Time to get out. I’m going to apply to be the STEM inspector. If you can’t beat them, join them.
Pfizer will beat us to market with RSV. Another VBU failure.
You're an idiot. They beat us to market with Men B and we dominate that market.
We had to sell oncology to get Bexsero. We did not develop it, Norvartis did. That's why it's successful.
Pfizer will beat us to market with RSV. Another VBU failure.
Pfizer will beat us to market with RSV. Another VBU failure.
beating someone to market might matter early on. The science, pricing and total portfolio probably matter more. Believe it or not representation of the product matters as well. Reps do matter and make a difference.
Metrics matter, but when they become unrealistic due to geographic market conditions people are force to lie. No one like to lie and cheat, that's what we are force to to.
No thanks! Pharma is a job you do for 2 years max out of school, until you find a real career. Any longer you get stuck at a dead end job making a fraction what you’re worth, or you become a lazy POS work 1/2 days and have zero self worth. I'll just let all you liberal arts grads, try to play doctor Better than working at starbucks I guess!
The VBU. It's changed from when Al managed it. Gone from good to, it sucks under new management.
Al resisted the change from true account management to pharma pill selling management metrics. Now we have a bunch of former managers from respiratory and other units enforcing the metrics from their units upon the vaccines division. Vaccines may do well no matter what, it would do better with a management that understood our customers needs- which senior management has blinders to. GSK always screws sales up.
Spot on here and sad!
We can only hope for another change, back to sanity, sooner than later for VBU.
Ok call center, have at it! Lol